Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of mRNA-6231 in Healthy Adults
NCT04916431Phase 1Completed
- Sponsor
- Moderna Inc
- Start
- Jul 2021
- Primary completion
- Aug 2022
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of mRNA-6231 in autoimmune diseases (3 arms), sponsored by Moderna Inc. Primary endpoint: Number of Participants with Adverse Events (AEs) and Serious AEs. Started Jul 2021; status: completed.
02
Drugs
mRNA-6231
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT04916431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04916431.